CVRx (NASDAQ:CVRX) Rating Lowered to Market Perform at William Blair

William Blair cut shares of CVRx (NASDAQ:CVRX) from an outperform rating to a market perform rating in a research note released on Wednesday, Marketbeat reports. William Blair also issued estimates for CVRx’s Q2 2024 earnings at ($0.57) EPS, Q3 2024 earnings at ($0.50) EPS, Q4 2024 earnings at ($0.49) EPS, FY2024 earnings at ($2.61) EPS, Q1 2025 earnings at ($0.53) EPS, Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.47) EPS and FY2025 earnings at ($1.98) EPS.

CVRX has been the topic of a number of other reports. JPMorgan Chase & Co. upped their target price on shares of CVRx from $31.00 to $36.00 and gave the company an overweight rating in a research report on Friday, January 26th. Piper Sandler upped their target price on shares of CVRx from $21.00 to $33.00 and gave the company an overweight rating in a research report on Friday, January 26th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus target price of $16.60.

CVRx Stock Up 8.7 %

Shares of NASDAQ CVRX opened at $9.22 on Wednesday. The firm’s 50-day simple moving average is $17.85 and its 200 day simple moving average is $20.88. The company has a market cap of $199.06 million, a price-to-earnings ratio of -3.73 and a beta of 1.35. The company has a quick ratio of 12.86, a current ratio of 14.25 and a debt-to-equity ratio of 0.38. CVRx has a 12-month low of $7.77 and a 12-month high of $33.13.

Insider Activity

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Paul Verrastro sold 2,545 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $21.91, for a total value of $55,760.95. Following the completion of the sale, the insider now directly owns 2,455 shares of the company’s stock, valued at $53,789.05. The disclosure for this sale can be found here. 18.30% of the stock is currently owned by company insiders.

Institutional Trading of CVRx

A number of large investors have recently bought and sold shares of the business. Valeo Financial Advisors LLC bought a new stake in CVRx during the 1st quarter worth approximately $346,000. Parkman Healthcare Partners LLC increased its stake in CVRx by 8.0% during the 4th quarter. Parkman Healthcare Partners LLC now owns 240,000 shares of the company’s stock worth $7,546,000 after purchasing an additional 17,880 shares in the last quarter. Trexquant Investment LP bought a new stake in CVRx during the 4th quarter worth approximately $426,000. Level Four Advisory Services LLC increased its stake in CVRx by 6.8% during the 4th quarter. Level Four Advisory Services LLC now owns 28,885 shares of the company’s stock worth $908,000 after purchasing an additional 1,844 shares in the last quarter. Finally, Jump Financial LLC bought a new stake in CVRx during the 4th quarter worth approximately $499,000. 75.27% of the stock is owned by institutional investors.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.